ClinicalTrials.gg

Burkitt Lymphoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 977 studies for Burkitt Lymphoma across more than 10 countries. 160 are recruiting or about to start. 246 of them are mainly about Burkitt Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 983 studies for Burkitt Lymphoma. How that becomes 975 here

This page counts the studies the registry files under Burkitt Lymphoma, and those it files under no condition that list Burkitt Lymphomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 983Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1List Burkitt Lymphoma as a condition, but the registry did not file them under itMost often written as “AIDS-Related Burkitt Lymphoma” (1). The registry filed them under other conditions only, most often HIV Infections (1).
  3. −7Match it another way1 name it in the title, 1 in a keyword, and 5 by a synonym or other text the search reads.
  4. 975The count on this page

Status

Completed
509
Recruiting
132
Terminated
127
Status unknown
76
Active, not recruiting
52
Withdrawn
49

Phase

Phase 1
438
Phase 2
419
Phase 3
76
Early Phase 1
29
Phase 4
5

Where

United States
725
China
102
Canada
62
France
42
Italy
41
United Kingdom
36

Who develops what

Add Burkitt Lymphoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 18 programs from 11 companies, 16 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Beijing Biotech, Amgen and AstraZeneca here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DexamethasoneRecent, repeated
Evidence
  • NCT07770698 · BeOne Medicines · Phase 2 · live · background · “Dexamethasone” · registered May 2026
  • NCT07570173 · Merck & Co., Inc · Phase 3 · live · background · “Dexamethasone” · registered Apr 2026
  • NCT02723994 · Incyte Corporation · Phase 2 · background · “Dexamethasone” · registered Mar 2016
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT06009107 · Juventas Cell Therapy Ltd. · Phase 2 · background · “Cyclophosphamide” · registered Aug 2023
  • NCT05537766 · Gilead Sciences · Phase 2 · background · “Cyclophosphamide” · registered Sep 2022
  • NCT02723994 · Incyte Corporation · Phase 2 · background · “Cyclophosphamide” · registered Mar 2016
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

14 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Anti-CD19/CD3 Bispecific Antibody MK-1045☆ Track1 live phase-3 study: NCT07570173Merck & Co., Inc

The 1 in phase 3 with the nearest primary completion, of 18 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Mar 2027 est.Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module · Beijing Biotech · Phase 2 main aimNCT07523555 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — primary endpoint: Incidence of dose-limiting toxicities (DLTs) by module and dose level · 96 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Burkitt Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 11 open · Alkylating agents 10 open · Antibody-drug conjugates (ADCs) 8 open · Corticosteroids 7 open · Tyrosine kinase inhibitors (TKIs) 5 open

Coming up

60studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 42 (32%) set no upper age limit and 77 (58%) stop at 75 or younger. 75 (57%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 132
AgeWomenMen
1054 (41%)54 (41%)
18128 (97%)128 (97%)
30103 (78%)103 (78%)
4092 (70%)92 (70%)
5091 (69%)91 (69%)
6587 (66%)87 (66%)
7569 (52%)69 (52%)
8551 (39%)51 (39%)

Across all 977 studies, recruiting or not: 42% stop at 75 or younger and 29% at 65; 46% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Burkitt Lymphoma studies take

Of 109 phase 1 interventional studies under Burkitt Lymphoma, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 161 mo38–90 · 109 studies—57 mo38–90 · 87 studies
Phase 1/264 mo50–114 · 50 studies——
Phase 281 mo41–119 · 92 studies—83 mo42–120 · 84 studies
Phase 3106 mo78–119 · 19 studies——
Interventional, no phase96 mo50–144 · 20 studies——
Observational35 mo25–114 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 977. Browse all 977 → or search them.